Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Fibulin-3 CRISPR/Cas9 KO Plasmid (h): sc-401978
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Fibulin-3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Fibulin-3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Fibulin-3 Antibody (C-3): sc-365224
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fibulin-3 CRISPR/Cas9 KO Plasmid (h) | sc-401978 | 20 µg | $397.00 |
Overview
EFEMP1 encodes fibulin-3, a secreted extracellular matrix glycoprotein that associates with elastic fibers and basement membrane components to regulate matrix assembly, cell–matrix adhesion, and tissue remodeling. Fibulin-3 modulates protease activity and extracellular matrix turnover, including interactions that influence MMP/ADAMTS-mediated remodeling, and it has been linked to signaling contexts such as TGF-β/SMAD that coordinate fibrosis and epithelial–mesenchymal programs. In human tissues, EFEMP1 expression is relevant to vascular and ocular homeostasis, and altered fibulin-3 levels have been associated with retinal degenerative phenotypes and changes in stromal architecture in cancer biology. These roles make EFEMP1 a useful entry point for studying extracellular matrix regulation, secreted protein networks, and microenvironment-dependent cellular behavior.
Fibulin-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EFEMP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EFEMP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EFEMP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Fibulin-3 protein expression.
This CRISPR knockout system enables efficient generation of EFEMP1-deficient cell models for investigation of Fibulin-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting EFEMP1 exon(s) critical for Fibulin-3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple EFEMP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Fibulin-3 CRISPR/Cas9 KO Plasmid (h) and Fibulin-3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EFEMP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Fibulin-3 HDR Plasmid (h) and Fibulin-3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EFEMP1 homology arms to support homology-directed repair at defined EFEMP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.